CTOs on the Move

True North Therapeutics

www.truenorthrx.com

 
True North Therapeutics is a pioneering biotechnology company selectively inhibiting the Complement pathway for diseases of high unmet clinical need. The companys lead monoclonal antibody, TNT009, targets the Classical Complement pathway, enabling selective inhibition of downstream phagocytosis, inflammation, and cell lysis. True North is currently focused on Complement-mediated rare diseases in the hematologic, renal, and neurological space. True North was formed in 2013 as a spin-out of iPierian.
  • Number of Employees: 5K-10K
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

True North Therapeutics raised $40M on 12/03/2015
True North Therapeutics raised $45M on 10/19/2016

Similar Companies

Codex DNA

Codex DNA is home to Gibson Assembly, and pioneering synthetic DNA/gene synthesis hardware, including the BioXp, the world’s first DNA printer. Our mission is to empower scientific researchers in both academic and commercial settings with the materials...

Modis Therapeutics

Modis Therapeutics is a biopharmaceutical company focused on developing disease-modifying therapies for rare genetic diseases with high unmet medical need.

Optimer Pharmaceuticals

Optimer Pharmaceuticals, Inc. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Clemson University Biomedical Engineering Innovation Campus

The Clemson University Biomedical Engineering Innovation Campus develops high-impact medical technology and devices for disease management and technology transfer from bench to bedside.